Drug intelligence / Profile preview

UMC119-01-05

Development stage: Preclinical
Lead developer: Meridigen Biotech
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

UMC119-01-05 is an allogeneic cell therapy product composed of ex vivo cultured human umbilical cord tissue-derived mesenchymal stem cells (UC-MSCs), developed by Meridigen Biotech. It is currently under investigation for the treatment of cerebral palsy (CP), particularly in newborns. The therapeutic mechanism is attributed to the cells' ability to migrate to sites of injury and secrete bioactive factors that provide immunomodulatory, anti-inflammatory, and neuroregenerative effects. These actions are intended to mitigate brain damage and promote functional recovery in patients with cerebral palsy by reducing neuroinflammation and supporting tissue repair.

Other names: UMC119-01UMC-119-01UMC 119-01umbilical cord-derived mesenchymal stem cellsUC-MSCs

Beyond the preview

Go deeper on UMC119-01-05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UMC119-01-05.

Explore the full profile